Skip to Content
Merck
CN

SML1642

DHED

≥98% (HPLC)

Synonym(s):

(17β)-10,17-Dihydroxy-estra-1,4-dien-3-one, 10β,17β-Dihydroxyestra-1,4-dien-3-one, 3,16-Dihydroxyandrost-5-ene-17,19-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H24O3
CAS Number:
549-02-0
Molecular Weight:
288.38
UNSPSC Code:
51111800
PubChem Substance ID:
329825983
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

DHED, ≥98% (HPLC)

SMILES string

O[C@@]12C(CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4O)=CC(C=C1)=O

InChI

1S/C18H24O3/c1-17-8-7-15-13(14(17)4-5-16(17)20)3-2-11-10-12(19)6-9-18(11,15)21/h6,9-10,13-16,20-21H,2-5,7-8H2,1H3/t13-,14-,15-,16-,17-,18+/m0/s1

InChI key

UIKDFTLKOKNUJP-UGDFAFBOSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -20 to -30°, c = 1 in methanol

color

white to light brown

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Application

DHED has been used to induce an increase of estrogen levels in 3K transgenic mice with Parkinson′s disease (PD)-like motor syndrome.

Biochem/physiol Actions

DHED (10β,17β-dihydroxyestra-1,4-dien-3-one) is an inactive prodrug that selectively produces estrogen solely in the brain. DHED is converted to 17β-estradiol in the brain by an enzyme only expressed in the CNS, but is inert in the rest of the body. DHED was found to provide neuroprotection in a rat stroke model and reversed neurological symptoms of estrogen deprivation such as memory problems in female rats lacking ovaries.
DHED is a substrate for nicotinamide adenine dinucleotide phosphate (NADPH)-dependent dehydrogenase/reductase. Its expression in the brain is correlated to neuroprotection functionality.
DHED is an inactive prodrug that selectively produces estrogen solely in the brain.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360Df

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000495855
0000495854
0000495854
0000495855
0000391887

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Molly M Rajsombath et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 39(38), 7628-7640 (2019-08-14)
Many studies report a higher risk for Parkinson's disease (PD) and younger age of onset in men. This, and the fact that the neuropathological process underlying PD symptoms may begin before menopause, suggests that estrogen-based hormone therapy could modify this
Laszlo Prokai et al.
Science translational medicine, 7(297), 297ra113-297ra113 (2015-07-24)
Many neurological and psychiatric maladies originate from the deprivation of the human brain from estrogens. However, current hormone therapies cannot be used safely to treat these conditions commonly associated with menopause because of detrimental side effects in the periphery. The

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service